CVS Health Corporation (CVS)
CVS: FY 2026 Margin Recovery, Well Covered Dividends, And Cheap Valuations
CVS remains a great Buy here, driven by the raised FY2025 adj EPS guidance and the robust outperformance against its healthcare peers despite the industrywide headwinds. Margin recovery is expected to accelerate from FY2026, supported by the Medicare Advantage four-star ratings, the upcoming ACA exit, and the repricing of group MA contracts. CVS' valuations remain discounted at current levels, with patient investors being paid rich dividend yields pending its upward re-rating.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health Delivers MBR Improvement: Is More Progress in the Cards?
CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.
Here's Why CVS Health (CVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health Posts Strong Q3 Earnings: How to Play the Stock Now?
CVS posts record Q3 revenues and a sharp EPS jump, lifting its 2025 outlook, while momentum builds across Aetna, Health Services and Pharmacy.
CVS Health Lifts Adjusted EPS Outlook: What's Driving It?
CVS raises its full-year EPS outlook after a strong quarter, driven by gains across all segments and solid pharmacy growth.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health: Undervalued And Ripe For Growth
CVS Health offers a compelling value and income opportunity, trading at a forward P/E under 12 with a 3.4% dividend yield. It delivered strong Q3 results, driven by Aetna's insurance segment and momentum in transparent PBM pricing via CostVantage. Management raised 2025 EPS guidance, projecting robust double-digit earnings growth. It also has a well-covered, growing dividend.
CVS Health reports Q3 earnings beat, raises full-year guidance
CVS Health Corp (NYSE:CVS) reported third quarter 2025 financial results on Wednesday, posting both revenue and adjusted earnings per share (EPS) above Wall Street expectations. For the quarter, CVS reported total revenue of $102.9 billion, up 7.8% from the same period last year and exceeding the consensus estimate of $98.29 billion.
CVS Health (CVS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
